Glenmark Pharmaceuticals gains on USFDA nod for Lacosamide tablets

The company has recieved tentative approval from USFDA for its Lacosamide tablets in dosages of 50mg, 100mg, 150mg and 200mg.

Shares of Glenmark Pharmaceuticals were up over 5% at Rs 992 on the Bombay Stock Exchange after the company today announced that it has recieved tentative approval by the United States Food & Drug Administration (USFDA) for its Lacosamide tablets in dosages of 50mg, 100mg, 150mg and 200mg.

The tablets are the generic version of Vimpat tablets of 50mg, 100mg, 150mg and 200mg of UCB, Inc., the company said in a release.

Glenmark will market this product upon receiving final approval of its Lacosamide tablets, 50 mg, 100mg, 150 mg and 200mg ANDA. The patent listed in the Orange Book for Vimpat tablets, 50 mg, 100mg, 150mg and 200mg is scheduled to expire on March 17, 2022, the release added.

The stock opened at Rs 970 and touched a high of Rs 995. At 12:45pm, over 1.5 million shares were traded on both the stock exchanges.